A Pilot Randomized, Controlled Trial of Metformin versus Insulin in Women with Type 2 Diabetes Mellitus during Pregnancy

Jerrie S. Refuerzo; Rose Gowen; Claudia Pedroza; Maria Hutchinson; Sean C. Blackwell; Susan Ramin

doi:10.1055/s-0034-1378144

American Journal of Perinatology, Inhaltsverzeichnis

Am J Perinatol 2015; 32(02): 163-170
DOI: 10.1055/s-0034-1378144

Original Article

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

A Pilot Randomized, Controlled Trial of Metformin versus Insulin in Women with Type 2 Diabetes Mellitus during Pregnancy

Jerrie S. Refuerzo

¹Division of Maternal Fetal Medicine, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Texas Health Science Center at Houston, Houston, Texas

,

Rose Gowen

²Department of Obstetrics, Gynecology and Reproductive Sciences, University of Texas Health Science Center at Brownsville, Brownsville, Texas

,

Claudia Pedroza

³Center for Clinical Research and Evidence-Based Medicine, University of Texas Health Science Center at Houston, Houston, Texas

,

Maria Hutchinson

¹Division of Maternal Fetal Medicine, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Texas Health Science Center at Houston, Houston, Texas

,

Sean C. Blackwell

¹Division of Maternal Fetal Medicine, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Texas Health Science Center at Houston, Houston, Texas

,

Susan Ramin

⁴Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, Texas

› Institutsangaben

Abstract

Objective Few studies support oral diabetic treatment in pregnant women with type 2 diabetes mellitus (T2DM). The objective of this study was to compare the effects of metformin versus insulin on achieving glycemic control and improving maternal and neonatal outcomes in pregnant women with T2DM.

Study Design A pilot randomized, controlled trial was conducted of metformin versus insulin for the treatment of T2DM during pregnancy. The primary outcome was glycemic control measured with hemoglobin A1c < 7% at delivery. Maternal and neonatal outcomes were compared between groups.

Results In this study, 8 women received metformin and 11 received insulin. All women in both groups achieved glycemic control by delivery (HgbA1c: metformin 5.96 ± 5.88 vs. insulin 6.34 ± 0.92%). There were similar rates of cesarean delivery, birth weights, neonatal intensive care unit admissions, respiratory distress syndrome, and neonatal dextrose treatment between groups. There was one case of fetal macrosomia in the insulin group, one case of shoulder dystocia in the metformin group and no cases of failed metformin therapy.

Conclusion In this pilot study, glycemic control was achieved in women who received metformin and insulin. Larger studies are needed to determine whether metformin can be considered a reasonable alternative to insulin in pregnant women with T2DM.

Keywords

type 2 diabetes mellitus - pregnancy - metformin

Volltext

Referenzen

References
1 Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002; 288 (14) 1723-1727
2 Checa MA, Requena A, Salvador C , et al; Reproductive Endocrinology Interest Group of the Spanish Society of Fertility. Insulin-sensitizing agents: use in pregnancy and as therapy in polycystic ovary syndrome. Hum Reprod Update 2005; 11 (4) 375-390
3 Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 2005; 65 (3) 385-411
4 Krentz AJ, Ferner RE, Bailey CJ. Comparative tolerability profiles of oral antidiabetic agents. Drug Saf 1994; 11 (4) 223-241
5 Goodarzi MO, BryerAsh M. Metformin revisited: reevaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents. Diabetes Obes Metab 2005; 7 (6) 654-665
6 Norman RJ, Wang JX, Hague W. Should we continue or stop insulin sensitizing drugs during pregnancy?. Curr Opin Obstet Gynecol 2004; 16 (3) 245-250
7 Klip A, Leiter LA. Cellular mechanism of action of metformin. Diabetes Care 1990; 13 (6) 696-704
8 Gestational diabetes mellitus. Practice Bulletin No. 137. American College of Obstetricians and Gynecologists. Obstet Gynecol 2013; 122: 406-416
9 Gabbe SG, Graves CR. Management of diabetes mellitus complicating pregnancy. Obstet Gynecol 2003; 102 (4) 857-868
10 Martorell R, Stein AD, Schroeder DG. Early nutrition and later adiposity. J Nutr 2001; 131 (3) 874S-880S
11 Strauss RS. Effects of the intrauterine environment on childhood growth. Br Med Bull 1997; 53 (1) 81-95
12 Whitaker RC, Dietz WH. Role of the prenatal environment in the development of obesity. J Pediatr 1998; 132 (5) 768-776
13 Jovanovic R, Jovanovic L. Obstetric management when normoglycemia is maintained in diabetic pregnant women with vascular compromise. Am J Obstet Gynecol 1984; 149 (6) 617-623
14 Glueck CJ, Goldenberg N, Streicher P, Wang P. Metformin and gestational diabetes. Curr Diab Rep 2003; 3 (4) 303-312
15 Glueck CJ, Goldenberg N, Streicher P, Wang P. The contentious nature of gestational diabetes: diet, insulin, glyburide and metformin. Expert Opin Pharmacother 2002; 3 (11) 1557-1568
16 Simmons D, Walters BN, Rowan JA, McIntyre HD. Metformin therapy and diabetes in pregnancy. Med J Aust 2004; 180 (9) 462-464
17 Lawrence JM, Andrade SE, Avalos LA , et al; Medication Exposure in Pregnancy Risk Evaluation Program (MEPREP) Study Group. Prevalence, trends, and patterns of use of antidiabetic medications among pregnant women, 2001-2007. Obstet Gynecol 2013; 121 (1) 106-114
18 Coetzee EJ, Jackson WP. Pregnancy in established non-insulin-dependent diabetics. A five-and-a-half year study at Groote Schuur Hospital. S Afr Med J 1980; 58 (20) 795-802
19 Ibrahim MI, Hamdy A, Shafik A, Taha S, Anwar M, Faris M. The role of adding metformin in insulin-resistant diabetic pregnant women: a randomized controlled trial. Arch Gynecol Obstet 2014; 289 (5) 959-965
20 Hickman MA, McBride R, Boggess KA, Strauss R. Metformin compared with insulin in the treatment of pregnant women with overt diabetes: a randomized controlled trial. Am J Perinatol 2013; 30 (6) 483-490
21 Lilford RJ, Thornton JG, Braunholtz D. Clinical trials and rare diseases: a way out of a conundrum. BMJ 1995; 311 (7020) 1621-1625
22 Wijeysundera DN, Austin PC, Hux JE, Beattie WS, Laupacis A. Bayesian statistical inference enhances the interpretation of contemporary randomized controlled trials. J Clin Epidemiol 2009; 62 (1) 13-21 , e5
23 Goodman SN. Introduction to Bayesian methods I: measuring the strength of evidence. Clin Trials 2005; 2 (4) 282-290 , discussion 301–304, 364–378
24 Langer O, Conway DL, Berkus MD, Xenakis EM, Gonzales O. A comparison of glyburide and insulin in women with gestational diabetes mellitus. N Engl J Med 2000; 343 (16) 1134-1138
25 Coetzee EJ, Jackson WP. Oral hypoglycaemics in the first trimester and fetal outcome. S Afr Med J 1984; 65 (16) 635-637
26 Coetzee EJ, Jackson WP. The management of non-insulin-dependent diabetes during pregnancy. Diabetes Res Clin Pract 1985– 1986; 1 (5) 281-287
27 Rowan JA, Hague WM, Gao W, Battin MR, Moore MP ; MiG Trial Investigators. Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med 2008; 358 (19) 2003-2015
28 Vanky E, Salvesen KA, Heimstad R, Fougner KJ, Romundstad P, Carlsen SM. Metformin reduces pregnancy complications without affecting androgen levels in pregnant polycystic ovary syndrome women: results of a randomized study. Hum Reprod 2004; 19 (8) 1734-1740
29 Glueck CJ, Wang P, Goldenberg N, Sieve-Smith L. Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Hum Reprod 2002; 17 (11) 2858-2864